Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody
Abstract RLYB212 is a human monoclonal anti‐human platelet antigen (HPA)‐1a immunoglobulin gamma 1 in clinical development as a subcutaneous injection for the prevention of maternal alloimmunization to fetal HPA‐1a leading to fetal and neonatal alloimmune thrombocytopenia (FNAIT). This analysis deve...
Saved in:
Main Authors: | Courtney Moc Willeford (Author), Krithika Shetty (Author), Douglas Sheridan (Author), Frank Engler (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies
by: Shufang Liu, et al.
Published: (2021) -
Transient Expression of a Recombinant Monoclonal Antibody in HEK293T Cells
by: Omid Mohammadian, et al.
Published: (2018) -
Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
by: Johannes Schropp, et al.
Published: (2019) -
A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults
by: Suping Niu, et al.
Published: (2022) -
Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model
by: Ninad Varkhede, et al.
Published: (2018)